蒙古国13价肺炎球菌结合疫苗接种的成本效果分析
蒙古国卫生部考虑将13价肺炎球菌结合疫苗(PCV13)纳入国家免疫规划,本研究采用年龄分层静态多队列模型,评估PCV13相比不接种疫苗的成本效果与预算影响。结果显示,从卫生系统角度看,ICER为每避免一个伤残调整生命年(DALY)52美元,从社会角度看可节省成本;保守情景下(不考虑间接效应)分别为79美元/DALY和19美元/DALY。结论认为引入PCV13具有高度成本效果,且在社会角度下可节省成本。
要点
- PCV13相比不接种,卫生系统角度ICER为52美元/DALY,社会角度可节省成本。
- 保守情景(不考虑间接效应)下,卫生系统角度79美元/DALY,社会角度19美元/DALY。
- 接种PCV13预计2016年花费约92万美元,此后每年约82万美元。
核心结论
- 在蒙古国国家免疫规划中引入PCV13相比不接种疫苗似乎具有高度成本效果,且在以Gavi提供的疫苗采购价格计算时从社会角度可节省成本。
- 尽管部分参数存在不确定性,PCV13引入的成本效果在一系列保守情景下仍然稳健。
- 获得高质量的国家数据将改善未来疫苗引入的经济学分析。
研究设计与样本
- 采用年龄分层静态多队列模型评估引入PCV13相比不接种PCV疫苗的增量成本效果比(ICER)。
- 评估了所有年龄三十个出生队列中肺炎球菌疾病各种临床表现(脑膜炎、肺炎、非脑膜炎非肺炎侵袭性肺炎球菌疾病和急性中耳炎)的风险。
- 分析同时考虑了卫生系统角度和社会角度。
- 基线情景假设采用3+0疫苗程序,疫苗价格为每剂3.30美元,基于Gavi疫苗联盟预先市场承诺尾价。
主要发现
- PCV13引入的ICER估计为每避免一个DALY 52美元(卫生系统角度),从社会角度可节省成本。
- 在不考虑间接效应的保守情景下,PCV13引入估计为每避免一个DALY 79美元(卫生系统角度),每避免一个DALY 19美元(社会角度)。
- 接种PCV13预计2016年花费约920,000美元,此后每年约820,000美元。
- 该规划可能使卫生部第一年直接疾病相关成本减少440,000美元,到2025年增至510,000美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 部分参数存在不确定性。
- 获得高质量的国家数据将改善未来疫苗引入的经济学分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Ministry of Health (MOH), Mongolia, is considering introducing 13-valent pneumococcal conjugate vaccine (PCV13) in its national immunization programme to prevent the burden of disease caused by Streptococcus pneumoniae. This study evaluates the cost-effectiveness and budget impact of introducing PCV13 compared to no PCV vaccination in Mongolia. METHODS: The incremental cost-effectiveness ratio (ICER) of introducing PCV13 compared to no PCV vaccination was assessed using an age-stratified static multiple cohort model. The risk of various clinical presentations of pneumococcal disease (meningitis, pneumonia, non-meningitis non-pneumonia invasive pneumococcal disease and acute otitis media) at all ages for thirty birth cohorts was assessed. The analysis considered both health system and societal perspectives. A 3+0 vaccine schedule and price of US$3.30 per dose was assumed for the baseline scenario based on Gavi, the Vaccine Alliance's advance market commitment tail price. RESULTS: The ICER of PCV13 introduction is estimated at US$52 per disability-adjusted life year (DALY) averted (health system perspective), and cost-saving (societal perspective). Although indirect effects of PCV have been well-documented, a conservative scenario that does not consider indirect effects estimated PCV13 introduction to cost US$79 per DALY averted (health system perspective), and US$19 per DALY averted (societal perspective). Vaccination with PCV13 is expected to cost around US$920,000 in 2016, and thereafter US$820,000 every year. The programme is likely to reduce direct disease-related costs to MOH by US$440,000 in the first year, increasing to US$510,000 by 2025. CONCLUSION: Introducing PCV13 as part of Mongolia's national programme appears to be highly cost-effective when compared to no vaccination and cost-saving from a societal perspective at vaccine purchase prices offered through Gavi. Notwithstanding uncertainties around some parameters, cost-effectiveness of PCV introduction for Mongolia remains robust over a range of conservative scenarios. Availability of high-quality national data would improve future economic analyses for vaccine introduction.
引用
- Sundaram N, Chen C, Yoong J, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia. Vaccine. 2017. PMID: 28109706. doi:10.1016/j.vaccine.2016.12.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。